The peril to U.S. leadership in world biomedical research, highlighted in the Dec. 5 editorial “Bad medicine,” is all the more pressing in view of developments in Japan, China, Singapore and South Korea, whose governments are maintaining or increasing their national biomedical research budgets.

The self-inflicted impoverishment of U.S. biomedical innovation is already contributing to the brain drain of U.S.-trained researchers and clinical scientists to these Asian countries, who will reap this windfall of talent that has benefited from the first-class scientific mentorship and development received at world-class American universities and research institutes. The United States’ future business and scientific prosperity is far too important to be pawns in such poorly played political chess.  

John A. Tessensohn, Osaka, Japan